Highs and lows of minimal residual disease in CLL
DM Stephens - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
Blood, The Journal of the American Society of Hematology, 2019•ashpublications.org
In this issue of Blood, Langerak et al report on the prognostic value of minimal residual
disease (MRD) status in elderly patients with comorbid chronic lymphocytic leukemia (CLL)
who were treated on the phase 3 CLL11 trial with chlorambucil plus rituximab (R-Chl) or
chorambucil plus obinutuzumab (G-Chl). 1 The authors found that high levels of MRD were
independently associated with shorter progression-free survival (PFS) and overall survival
(OS) and reported that the G-Chl regimen was superior to R-Chl in terms of inducing MRD …
disease (MRD) status in elderly patients with comorbid chronic lymphocytic leukemia (CLL)
who were treated on the phase 3 CLL11 trial with chlorambucil plus rituximab (R-Chl) or
chorambucil plus obinutuzumab (G-Chl). 1 The authors found that high levels of MRD were
independently associated with shorter progression-free survival (PFS) and overall survival
(OS) and reported that the G-Chl regimen was superior to R-Chl in terms of inducing MRD …
In this issue of Blood, Langerak et al report on the prognostic value of minimal residual disease (MRD) status in elderly patients with comorbid chronic lymphocytic leukemia (CLL) who were treated on the phase 3 CLL11 trial with chlorambucil plus rituximab (R-Chl) or chorambucil plus obinutuzumab (G-Chl). 1
The authors found that high levels of MRD were independently associated with shorter progression-free survival (PFS) and overall survival (OS) and reported that the G-Chl regimen was superior to R-Chl in terms of inducing MRD-negative remissions. 2 On the basis of these findings and the growing pool of data about posttherapy MRD status in CLL patients, the authors suggest that MRD has the
ashpublications.org
